MedinCell is a technological pharmaceutical company, focusing on useful innovation in order to optimize the efficiency of medical treatments and make them accessible all over the world. MedinCell has developed its patented BEPO® technology, which will allow for the arrival of a new generation of long-acting injectable medicines, lasting from a few days to several months. Developed in partnership with a number of pharmaceutical groups, the first treatments using BEPO® technology are already undergoing clinical trials. Based in Montpellier, MedinCell currently has around 100 employees as of the end of 2017, representing more than 25 nationalities.